Before We Start
HIV — a virus whose life cycle is also its treatment map
HIV (Human Immunodeficiency Virus) infects and gradually destroys CD4+ T cells, the coordinating cells of the immune system, leaving the body progressively unable to fight infections it would normally handle easily. But what makes HIV such a well-understood teaching case is that its life cycle unfolds as four clearly sequential steps — and modern antiretroviral therapy was built by designing a drug to block each one.
This matters clinically for a specific reason: HIV cannot be cleared by the immune system alone, and current medicine cannot cure it either. Understanding exactly why — which step in the life cycle makes the infection permanent — is one of the most frequently tested concepts in virology and nursing pharmacology alike.
💡 Memory Trick
CD4 + CCR5/CXCR4 → RT (RNA → DNA) → Integrase (inserts) → Protease (matures).
Read the chain left to right and you have the entire life cycle in order — and each arrow is exactly where one drug class intervenes. Binding needs a receptor and a coreceptor. Reverse transcriptase converts the genome format. Integrase inserts it permanently. Protease finishes the job. Four steps, four drug classes, one chain to memorize.
The Four Steps
Life cycle stage, mechanism, and which drug class blocks it
1. Binding & Fusion
gp120 binds CD4 plus a coreceptor, then the viral envelope fuses with the cell
HIV's surface protein, gp120, first binds to the CD4 receptor on the host T cell. Binding CD4 alone is not enough — gp120 also needs to bind a second receptor, a coreceptor, which is either CCR5 or CXCR4 depending on the strain of virus. Only once both connections are made does the viral envelope fuse with the host cell membrane, allowing the virus to inject its contents into the cell.
Drug classes that block this step: CCR5 antagonists (such as maraviroc) physically occupy the CCR5 coreceptor so gp120 cannot bind it, stopping entry before it starts — regardless of how much CD4 is available. Fusion inhibitors (such as enfuvirtide) act slightly later in the same step, preventing the actual membrane fusion event even if binding has already occurred.
🧬 Maraviroc blocks CCR5 specifically — it does nothing to CD4 itself. This is why a coreceptor antagonist only works against CCR5-tropic strains of HIV; a strain that instead uses CXCR4 as its coreceptor would not be stopped by maraviroc, which is exactly why coreceptor tropism testing is done before this drug class is prescribed.
2. Reverse Transcription
An error-prone enzyme converts HIV's RNA genome into DNA
HIV is a retrovirus, meaning its genetic material is RNA rather than DNA — but the host cell's machinery can only read and copy DNA. Reverse transcriptase, an enzyme HIV carries into the cell, solves this by converting the single-stranded RNA genome into double-stranded DNA. Critically, reverse transcriptase has no proofreading ability, so every round of replication introduces new copying errors into the viral genome.
Drug classes that block this step: Two distinct drug classes both target reverse transcriptase, but through different mechanisms. NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors) are faulty DNA building blocks that get incorporated into the growing DNA chain and then stop it from extending further. NNRTIs (non-nucleoside reverse transcriptase inhibitors) instead bind directly to the enzyme itself at a separate site, distorting its shape so it cannot function.
🧬 The lack of proofreading is precisely why HIV mutates so fast and why drug resistance develops so easily on a single medication — this is the core reason modern HIV treatment always combines drugs from multiple classes rather than relying on any one drug alone.
3. Integration
Integrase inserts the new viral DNA permanently into the host chromosome
Once reverse transcription produces viral DNA, that DNA still has to enter the cell's nucleus and become part of the host's own genome to be used. Integrase, another enzyme HIV brings into the cell, cuts the host chromosome and splices the viral DNA directly into it. Once integrated, the viral DNA — now called a provirus — becomes a permanent part of that cell's genetic material, indistinguishable from the host's own DNA by the cell's normal machinery.
Why this step is the one that matters most clinically: this is the exact step that makes HIV impossible to cure with any current treatment. The integrated provirus can lie dormant (latent) inside a resting T cell for years, invisible to the immune system and to antiretroviral drugs alike, only to reactivate later. Treatment can suppress active viral replication indefinitely, but it cannot remove DNA that is already woven into the host genome.
Drug class that blocks this step: Integrase inhibitors bind directly to the integrase enzyme, physically preventing it from splicing viral DNA into the host chromosome — stopping new integration events, though they have no effect on integration that has already occurred in previously infected cells.
🧬 This is the single most important distinction in the whole lesson: reverse transcription only changes the genome's chemical format from RNA to DNA — it does not make the infection permanent by itself. Integration is the step that does.
4. Maturation
Protease cleaves a long polyprotein into working viral components
The infected cell's own machinery now reads the integrated viral DNA and produces new viral RNA and proteins — but the proteins are initially made as one long, non-functional chain called a polyprotein (Gag-Pol). Protease, the final HIV enzyme in this sequence, cleaves that long chain into its separate functional pieces — the individual structural and enzymatic proteins a new virus actually needs. Only after this cleavage can the pieces assemble into a mature, infectious virion capable of going on to infect another cell.
Drug class that blocks this step: Protease inhibitors bind to the protease enzyme's active site, preventing it from cleaving the polyprotein. New viral particles still get assembled and released from the cell, but they remain immature and non-infectious — structurally present but incapable of infecting a new cell.
🧬 Protease inhibitors are a good example of a drug that stops the disease process without stopping viral particle production outright — the virus still tries to replicate, it just fails at the final quality-control step.
🏥 Applied Scenario
A patient is newly prescribed maraviroc as part of a combination HIV treatment regimen. A nursing student caring for this patient wants to understand exactly what maraviroc does — and how that's different from another drug on the same regimen, a protease inhibitor.
Step 1
Identify what maraviroc targets: Maraviroc is a CCR5 antagonist. It blocks the CCR5 coreceptor on the host T cell, which HIV needs to bind alongside CD4 in order to complete the binding and fusion step. Without CCR5 available to bind, the virus cannot enter the cell at all — this is the very first step of the entire life cycle.
Step 2
Compare against the protease inhibitor: A protease inhibitor acts at a completely different point — the last step of the life cycle, maturation. It does not stop the virus from entering the cell, replicating its genome, or integrating into the host chromosome. It only prevents new viral particles from becoming infectious once they're already being assembled and released.
Step 3
Explain why both drugs are used together: Combining drugs that act at different life cycle steps means the virus is attacked at multiple points simultaneously. Even if a mutation develops that lets the virus resist one drug, the other drug — acting on a completely different step — still blocks it. This is the entire rationale behind combination antiretroviral therapy.
Step 4
Conclusion: Maraviroc stops the infection before it can start in a given cell. The protease inhibitor lets the infection proceed through most of its cycle but sabotages the final product. Two entirely different mechanisms, two entirely different points in the same four-step chain — which is exactly why understanding the life cycle in sequence makes every HIV drug class make sense at a glance.
📌 Exam Application
HIV life cycle sequencing and drug class matching are frequently tested together:
Sequencing: "Place the following HIV life cycle steps in the correct order" — expect binding/fusion, reverse transcription, integration, and maturation to be given out of order, testing whether you know the actual sequence rather than just the four names.
Drug class matching: "A patient is prescribed an integrase inhibitor. At which step of the HIV life cycle does this drug act?" → Integration — it blocks integrase from inserting viral DNA into the host chromosome.
Clinical reasoning: "Why can HIV not be cured with current antiretroviral therapy?" → Because integration permanently inserts viral DNA into the host genome, where it can remain latent and undetectable, and no current drug can remove DNA already integrated into a cell.
Mechanism distinction: "How do NRTIs and NNRTIs differ, despite both targeting reverse transcriptase?" → NRTIs are faulty building blocks incorporated into the growing DNA chain that stop its extension; NNRTIs instead bind the enzyme directly at a separate site and distort its shape.
⚠️ The Trap — Confusing Which Step Causes Permanent Latency
A common exam trap asks students to identify which step of the HIV life cycle is responsible for the infection being permanent and incurable. Many students answer "reverse transcription," reasoning that this is the step where the virus's genetic material fundamentally changes, so it must be the point of no return.
Why this is wrong: Reverse transcription only converts the genome's chemical format — RNA into DNA. That DNA is not yet part of the host cell's genome; at this stage it exists as free-floating viral DNA in the cell's cytoplasm, and if the process were interrupted here, the infection in that particular cell could theoretically still be stopped before doing lasting damage.
The correct answer: Integration is the step that establishes permanent latency. It is only once integrase splices the viral DNA into the host cell's own chromosome that the viral genetic material becomes truly indistinguishable from and inseparable from the host's own DNA — at that point, no drug or immune response can remove it without also damaging the host cell's own genome. This is why every current HIV treatment target is described as suppressive, not curative.
How to avoid the trap: Ask yourself specifically "does this step make the viral DNA part of the host chromosome, or does it just change the genetic material's format?" Reverse transcription only changes format. Integration is what makes it permanent.
✓ Quick Self-Test
Answer before checking:
1. What two things does HIV's gp120 protein bind to during the first step of infection?
2. What does reverse transcriptase do, and why is it especially error-prone?
3. What does integrase do, and why does this step matter clinically more than any other?
4. What does protease do during the maturation step, and what happens to new viral particles if it's blocked?
5. Which drug class specifically targets the CCR5 coreceptor, and what is an example drug?
Answers:
1. CD4, plus a coreceptor — either CCR5 or CXCR4, depending on the viral strain.
2. It converts HIV's single-stranded RNA genome into double-stranded DNA; it is error-prone because it has no proofreading ability, so copying mistakes are never corrected, driving HIV's high mutation rate and rapid drug resistance.
3. Integrase inserts the newly made viral DNA into the host cell's own chromosome, establishing latency — this is the specific step that makes HIV impossible to cure with current treatment, since the virus becomes permanently woven into the host's own genetic material.
4. Protease cleaves the long Gag-Pol polyprotein into its separate functional pieces, which is required to assemble a mature, infectious virus. If protease is blocked, new viral particles are still produced and released, but they remain immature and non-infectious.
5. CCR5 antagonists; maraviroc is the example drug.
🔭 Beyond the Four Core Classes
Two newer antiretroviral classes have since emerged, beyond the four covered in this lesson. Capsid inhibitors (such as lenacapavir) target the protein shell that protects HIV's genetic material, interfering with multiple steps of the life cycle at once rather than a single stage. Post-attachment inhibitors work at the very first step, blocking a conformational change gp120 needs after initially touching CD4 — a distinct mechanism from CCR5 antagonists, which instead block the coreceptor itself. Both newer classes are typically reserved for patients whose HIV has developed resistance to multiple drugs from the four core classes above.